Recent Research Analysts’ Ratings Updates for LeMaitre Vascular (LMAT)

LeMaitre Vascular (NASDAQ: LMAT) recently received a number of ratings updates from brokerages and research firms:

• 11/5/2026 – LeMaitre Vascular had its price target lowered by Wells Fargo & Company from $94.00 to $86.00. They now have an “equal weight” rating on the stock.
• 11/5/2026 – LeMaitre Vascular was given a new $110.00 price target by Seaport Research Partners.
• 11/5/2026 – LeMaitre Vascular had its “market outperform” rating reaffirmed by Citigroup.
• 11/5/2026 – LeMaitre Vascular is now covered by Citizens Jmp. They set a “market outperform” rating and a $110.00 price target on the stock.
• 10/23/2026 – LeMaitre Vascular was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 10/8/2026 – LeMaitre Vascular was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.

LeMaitre Vascular Stock Down 3.7%

Shares of LeMaitre Vascular stock traded down $3.10 during trading hours on Friday, hitting $80.39. The company had a trading volume of 94,053 shares, compared to its average volume of 279,021. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The company’s 50-day moving average is $81.46 and its two-hundred day moving average is $94.14. The company has a market cap of $1.84 billion, a P/E ratio of 29.23, a price-to-earnings-growth ratio of 2.54 and a beta of 0.51. LeMaitre Vascular, Inc. has a twelve month low of $78.22 and a twelve month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.04). LeMaitre Vascular had a net margin of 23.51% and a return on equity of 15.57%. The company had revenue of $67.97 million during the quarter, compared to analysts’ expectations of $67.39 million. During the same period last year, the firm earned $0.75 earnings per share. LeMaitre Vascular’s revenue was up 11.3% on a year-over-year basis. Analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, November 19th. This represents a $1.00 annualized dividend and a yield of 1.2%. LeMaitre Vascular’s payout ratio is 36.36%.

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.